NCT05535413View on ClinicalTrials.gov

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

July 31, 2025

Conditions
Metastatic HER2 Negative Breast CarcinomaBrain MetastasesCapecitabineUDT1
Interventions
DRUG

UTD1 combined with capecitabine

"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."

Trial Locations (1)

410000

RECRUITING

Quchang Ouyang, Changsha

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER